Alex Federico

No ORCID on file · 1 paper in corpus
case-report 2024
Journal of personalized medicine ·doi:10.3390/jpm14101052

BACKGROUND: Most patients with ovarian cancer relapse within 2 years. Prospective randomized trials, such as DESKTOP III and SOC-I, have shown the role of secondary cytoreduction in improving oncological outcomes in selected patients, when …